Search

Your search keyword '"Namakydoust A"' showing total 120 results

Search Constraints

Start Over You searched for: Author "Namakydoust A" Remove constraint Author: "Namakydoust A"
120 results on '"Namakydoust A"'

Search Results

2. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

3. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

4. A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma

5. A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma

6. Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions

7. COVID-19 in patients with lung cancer

8. SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas

10. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

12. Figure S2 from The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

13. Supplementary Legend from The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

14. Figure S2 from The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

15. Data from The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

16. Table S1 from The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

17. Final Analysis of Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression Trial - A Randomized Study of Stereotactic Body Radiotherapy for Oligoprogressive Metastatic Lung and Breast Cancers

18. Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228

19. 1018P Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients

22. The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

24. COVID-19 in patients with lung cancer

25. SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas

26. Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228

27. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

29. Final Analysis of Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression Trial - A Randomized Study of Stereotactic Body Radiotherapy for Oligoprogressive Metastatic Lung and Breast Cancers

30. Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions

31. Corrigendum to “Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions” [Lung Cancer 159 (2021) 66–73]

32. Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression ― Interim Analysis of the First Randomized Study of Stereotactic Body Radiotherapy in Patients With Oligoprogressive Metastatic Cancers of the Lung and Breast

33. Targeting NFE2L2/KEAP1Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228

34. Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade

35. Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression ― Interim Analysis of the First Randomized Study of Stereotactic Body Radiotherapy in Patients With Oligoprogressive Metastatic Cancers of the Lung and Breast

36. The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

37. Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer.

38. The Genomic Landscape of

39. The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

40. MA06.08 A Safety Study of Avelumab plus SBRT in Malignant Mesothelioma

42. Corrigendum to 'Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions' [Lung Cancer 159 (2021) 66–73]

43. The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

44. A07 The Genomic Landscape of SMARCA4 Alterations and Association with Patient Outcomes in Lung Cancer

45. Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer

46. MA06.08 A Safety Study of Avelumab plus SBRT in Malignant Mesothelioma

47. A07 The Genomic Landscape of SMARCA4 Alterations and Association with Patient Outcomes in Lung Cancer

48. Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade

49. P1.01-122 A Clinical Utility Study of Plasma DNA Next Generation Sequencing Guided Treatment of Uncommon Drivers in Advanced Non-Small-Cell Lung Cancers

50. P1.01-122 A Clinical Utility Study of Plasma DNA Next Generation Sequencing Guided Treatment of Uncommon Drivers in Advanced Non-Small-Cell Lung Cancers

Catalog

Books, media, physical & digital resources